---
title: "double-hit in DLBCL"
slug: "double-hit-in-dlbcl"
date: "2023-07-24"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[Genetics and Molecular Subtypes of Diffuse large B-cell lymphoma]]

# double-hit in DLBCL

- [[High-grade B-cell lymphoma]] w/ _MYC & BCL2_ &/or BCL6 translocations by FISH (formerly â€œ[[double-hit in DLBCL]]â€) represent âˆ¼8% of all DLBCL & have poorer prog.
- IHC detected [[double_expressors.md|double expressors]] (MYC >40% BCL2 >70%) may be assoc w/ â†“ prog (JCO 2012;30:3460).
- [[clinical_features_of_double-hit_and_double-expressor_dlbcl.md|Clinical Features of Double-HIT and Double-Expressor DLBCL]]
- è¦æ˜ç¢ºæ’é™¤ DHLï¼Œéœ€è¦å°æ‰€æœ‰ä¾µè¥²æ€§æ·‹å·´ç˜¤æª¢é«”é€²è¡Œ FISH æª¢æ¸¬ï¼šä½†å¯ä»¥å…ˆçœ‹çœ‹æ˜¯ä¸æ˜¯ GCBï¼Œå†çœ‹ä¸€ä¸‹ MYC/BCL2 Positive by IHC
  - ![Figure: height:450px](https://i.imgur.com/stFlToQ.png) : Suggested algorithm for the diagnosis of double-hit lymphoma in resource-poor settings. BCL2 indicates B-cell CLL/lymphoma 2; BCL6, B-cell CLL/lymphoma 6; DLBCL, diffuse large B-cell lymphoma; FISH, fluorescence in situ hybridization; GCB, germinal center B cell; HGBL, high-grade B-cell lymphoma; IHC, immunohistochemistry.
  - cf. [[double_expressors]]

## Treatment

- Identify DHL/THL (MYC-R/BCL2-R) (especially GCB)
- Identify DEL
- DHL/THL: intensive chemotherapy: lenalidomide (DA-EPOCH-R / R-CODOX-M/IVAC/ R-HyperCVAD)
- Non-GCB + DEL: smart start protocol, R-CHOP + BTKi
- Non-GCB, age less than 60-65 years: R-CHOP + BTKi
- ABC, age > 60 years, man, IPI of 3-5: Pola-R-CHP
- A subset of patients with ABC type: R-CHOP + Velcade
- IPI of 3-5 and fit: DA-EPOCH-R, frontline ASCT in IPI of 4-5 ?
- Future perspectives: molecular clustering, ctDNA, next generation immunotherapy (CAR T-cell therapy,...)

---

- [[robust.md|ROBUST]] : A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
- [[phoenix.md|Phoenix]]: Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma: çœ‹èµ·ä¾†æ˜¯ OS å¥½åƒæ²’ä»€éº¼å·®ğŸ˜‚
- [[polarix.md|POLARIX]]: çœ‹èµ·ä¾†æ˜¯ OS å¥½åƒæ²’ä»€éº¼å·®ğŸ˜‚
- [[l-mind.md|L-MIND]]: Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
  - single-arm, objective response: 34 (43%; 32â€“54) had a complete response and 14 (18%; 10â€“28) had a partial response
